WuXi XDC Achieves Remarkable Wins at 2025 World ADC Awards for CDMO and CRO

WuXi XDC Triumphs at the World ADC Awards 2025

On November 6, 2025, WuXi XDC Cayman Inc. was celebrated at the 2025 World ADC Awards, taking home the prestigious title of "Best CDMO" for the third consecutive year and winning "Best CRO" for the first time. This year’s event was significant as WuXi XDC was the only service company to secure both honors, underlining its supremacy in the bioconjugates sector.

The World ADC Awards are pivotal in the global ADC industry, acknowledging those who have made substantial contributions. The award ceremony also marked a gathering of experts from around the world to discuss the latest developments and innovations in antibody-drug conjugates. Dr. Jimmy Li, CEO of WuXi XDC, expressed profound gratitude, stating, "We are honored to receive such recognition, which reflects not only our dedication to innovation but also builds the trust of our customers in our capabilities."

WuXi XDC is particularly noted for its innovative one-stop CRDMO services and advanced research capabilities that push the boundaries of bioconjugate development. The company specializes in enabling customers to conduct a range of R&D activities, focusing on groundbreaking areas such as bispecific ADCs and dual-payload ADCs. Their extensive expertise has been crucial in delivering several complex bioconjugate projects, cementing their reputation as industry leaders.

To support the rapidly evolving bioconjugate landscape, WuXi XDC has developed cutting-edge technologies such as the WuXiDARx™ platform and X-LinC technology. These innovations facilitate efficient conjugation and significantly streamline ADC development processes, alleviating the need for extensive antibody engineering. The WuXiDARx™ platform is designed to enhance efficiency and lower production costs, while X-LinC showcases exceptional stability and reaction kinetics.

WuXi XDC's comprehensive approach ensures seamless collaboration throughout the development lifecycle, minimizing risks and maximizing efficiency. Impressively, they have supported global clients in expediting ADCs from the DNA stage to IND applications within just 15 months, and from late-stage development to BLA approvals in as few as 24 to 36 months.

Emphasizing its global strategy, WuXi XDC has implemented a “Global Dual-Sourcing” approach, allowing one-stop manufacturing within its Wuxi facility. This strategy ensures product reliability through a centralized quality assurance system. Additionally, the company's new site in Singapore is set to meet GMP standards by mid-2026, ready to tackle the diverse supply chain needs of their clients.

According to their latest financial report, WuXi XDC has broadened its global reach, now serving 563 clients and aiding in nearly 100 IND submissions. Notably, 13 of the top 20 global pharmaceutical companies (ranked by their 2024 revenues) have engaged in various project phases with WuXi XDC, showcasing its substantial market share of over 22% within the global CRDMO sector.

In conclusion, WuXi XDC's outstanding achievements at the World ADC Awards highlight its pivotal role in advancing the bioconjugate industry. With continuous innovations and a steadfast commitment to excellence, WuXi XDC is poised to empower global clients in their pursuit of innovative therapies and contribute positively to patient well-being. For more detailed information about WuXi XDC, visit www.wuxixdc.com.